A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.

The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.
AuthorsJ Skillings, C Cripps, E Eisenhauer, J Pater, S Verma, D Walde
JournalInvestigational new drugs (Invest New Drugs) Vol. 9 Issue 1 Pg. 79-82 (Feb 1991) ISSN: 0167-6997 [Print] UNITED STATES
PMID1827434 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Menogaril
  • Nogalamycin
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Drug Evaluation
  • Humans
  • Injections, Intravenous
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Menogaril
  • Middle Aged
  • Nogalamycin (administration & dosage, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: